News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuvilex Can Benefit From Passage of This Week's Medical Marijuana Bill


4/10/2013 11:57:47 AM

NEW YORK, NY--(Marketwired - April 10, 2013) - Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary Medical Marijuana Sciences, Inc. received some good news this week as Maryland lawmakers passed a bill allowing medical marijuana programs at research centers. The Silver Spring, Maryland, biotechnology firm can take full advantage of the new measure as soon as Maryland Governor, Martin O'Malley, signs the bill which he has indicated he is likely to do.

This news clears the way for Nuvilex to get working more expeditiously on its research at Medical Marijuana Sciences. Prior to this measure, company officials had a long road of planning ahead of them to set up the facilities capable of doing the type of research the subsidiary has planned and remain free from prosecution. This bill will remove a large hurdle.

There is a real snowball effect going on in the country right now, and opinions continue to swing more and more toward legalizing the drug. In a Pew Research Center poll late last week, 52% of Americans now favor legalizing marijuana. This is the first time a majority of Americans have favored marijuana's legalization in this poll, and according to Pew, the question has been asked in polls since 1969. Estimates are that the marijuana industry will see revenues exceeding $3-billion by 2015 and double that by 2018. The marijuana snowball is rolling, and rolling fast!

In November, voters in both Washington and Colorado made the use of marijuana legal, and now 18 states and the District of Columbia have legalized marijuana for medicinal purposes or have legalized it altogether in the cases of Washington and Colorado. Nuvilex COO, Dr. Gerald Crabtree said Maryland's bill passing is good news for the company's future:

"As more states legalize the use of marijuana for medicinal purposes, it facilitates more and more our planned pursuit of treatments for serious and deadly diseases, like pancreatic and brain cancers that use components of cannabis...

Continue reading this article at www.stockhousegroup.com/features

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES